Drug development of an affinity enhanced, broadly neutralizing heavy chain-only antibody that restricts SARS-CoV-2 in rodents
Bert Schepens, Loes van Schie, Wim Nerinckx, Kenny Roose, Wander Van Breedam, Daria Fijałkowska, Simon Devos, Wannes Weyts, Sieglinde De Cae, Sandrine Vanmarcke, Chiara Lonigro, Hannah Eeckhaut, Dries Van Herpe, Jimmy Borloo, ANDREZA ESTEFANY DA SILVA OLIVEIRA, , Xavier Saelens
The paper describes the development of a broadly neutralizing antibody, XVR011, effective against SARS-CoV-2 and its variants in animal models.
bioRxiv · Mar 8, 2021 · PreprintMolecular Biology